[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Theken Companies LLC\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":120},{"warningLetters":4,"total":119},[5,31,53,76,98],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},426,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-12-15T05:00:00Z\">12\u002F15\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-12-12T05:00:00Z\">12\u002F12\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Falbertsons-companies-incorporated-720465-12122025\">The Albertsons Companies Incorporated\u003C\u002Fa>","Human Foods Program","Infant Botulism Outbreak","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Susan Morris\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>The Albertsons Companies Incorporated\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>M.S 10501 P.O. Box 29093\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Phoenix\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85038\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>December 12, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>CMS #720465\u003C\u002Fp>\u003Cp>Dear Ms. Morris:\u003C\u002Fp>\u003Cp>Beginning in November 2025, the U.S. Food and Drug Administration (FDA), in collaboration with the Centers for Disease Control and Prevention (CDC), the California Department of Public Health (CDPH), Infant Botulism Treatment and Prevention Program (IBTPP), and state and local partners, has been investigating a multistate outbreak of infant botulism linked to ByHeart Whole Nutrition Infant Formula. As of December 10, 2025, CDC reported that 51 infants from 19 states have suspected or confirmed infant botulism.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Infants range from 16 to 264 days of age. Based on epidemiological evidence, CDC has determined that ByHeart Whole Nutrition Infant Formula was the source of this multistate infant botulism outbreak.\u003C\u002Fp>\u003Cp>The presence of \u003Cem>Clostridium botulinum\u003C\u002Fem> in ByHeart Whole Nutrition Infant Formula, as evidenced by the recent foodborne outbreak, causes these products to be adulterated within the meaning of section 402(a)(1) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. § 342(a)(1)] in that they bear or contain an added poisonous or deleterious substance which may render them injurious to health.\u003C\u002Fp>\u003Cp>On November 8, 2025, ByHeart Inc. (ByHeart) initiated a voluntary recall of \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots of its ByHeart Whole Nutrition Infant Formula. As a consignee of the recalled products, The Albertsons Companies Incorporated (Albertsons) was notified in writing on November 8, 2025, of this voluntary recall. On November 11, 2025, ByHeart expanded the recall to all ByHeart Whole Nutrition Infant Formula, including all unexpired lots of formula cans and single-serve “anywhere pack” sticks. Albertsons was notified in writing on November 11, 2025, that the scope of the voluntary recall had expanded to include all ByHeart infant formula products. Despite these recall notifications, subsequent visits by regulators confirmed that recalled ByHeart Whole Nutrition Infant Formula remained available for purchase on shelves at \u003Cstrong>(b)(4)\u003C\u002Fstrong> Albertsons stores, including Albertson’s, Star Market, Jewel-Osco, Acme, Safeway, and Shaw’s, across 11 states well after the recall was initiated and subsequently expanded. The receipt in interstate commerce of adulterated food, and the delivery or proffered delivery thereof for pay or otherwise, is a violation of section 301(c) of the FD&amp;C Act [21 U.S.C. § 331(c)]. You can find the FD&amp;C Act and its implementing regulations through links on FDA’s home page at https:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\u003Cp>\u003Cstrong>Infant Botulism Investigation\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Infants can develop infant botulism when a baby swallows \u003Cem>Clostridium botulinum\u003C\u002Fem> spores that grow in the immature gut and produce toxin. Most infants with infant botulism will initially develop constipation, poor feeding, loss of head control, and difficulty swallowing, which can progress to difficulty breathing and respiratory arrest. Symptoms of infant botulism, which is diagnosed clinically, can take as long as several weeks to develop following formula ingestion.\u003C\u002Fp>\u003Cp>State and local public health officials are interviewing caregivers about the foods their infants consumed during the month prior to illness onset. All 51 previously reported infant botulism cases were infants who had been fed ByHeart Whole Nutrition Infant Formula before becoming sick.\u003C\u002Fp>\u003Cp>As part of its onsite inspections, FDA collected and is currently analyzing unopened product samples. This analysis is ongoing, and results will be shared as they become available. Additional testing by FDA, CDC, and state partners is also underway, with results expected in the coming weeks. Because detection of \u003Cem>Clostridium botulinum\u003C\u002Fem> in infant formula is scientifically complex, a negative test result does not rule out the presence of the bacteria in the product.\u003C\u002Fp>\u003Cp>\u003Cstrong>Receipt and Offer of Adulterated Foods\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As noted above, FDA investigators and state and local partners reported that recalled ByHeart formula continued to be found on Albertsons store shelves in multiple locations across multiple states. FDA and state partners have worked with retailers to ensure an effective recall and immediate removal of these products from all store shelves nationwide. All ByHeart infant formula products have been recalled, including all formula cans and single-serve “anywhere pack” sticks, and these products must not be available for sale in stores or online. The receipt in interstate commerce of adulterated food, and the delivery or proffered delivery thereof, is a violation of section 301(c) of the FD&amp;C Act [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>As a participant in the supply chain, your firm should take prompt and effective action when notified of a product recall. Once your firm has been made aware of a recall or potential safety issue, you should take action to immediately remove the affected product from distribution and sale, cease all further shipment or use, and implement all necessary measures to prevent further exposure to consumers or downstream distribution.\u003C\u002Fp>\u003Cp>However, based on FDA’s review of information from state and local partners, the Agency determined that recalled ByHeart Whole Nutrition Infant Formula remained on shelves at \u003Cstrong>(b)(4)\u003C\u002Fstrong> Albertsons store locations across 11 states from November 12 to November 19, 2025. This represents a period of \u003Cstrong>(b)(4)\u003C\u002Fstrong> days after Albertsons was first notified of the initial recall and \u003Cstrong>(b)(4)\u003C\u002Fstrong> days after Albertsons was notified of the recall expansion. State and local partners reported several explanations offered by Albertsons store associates for the continued presence of the recalled product, including lack of awareness of the recall notice, confusion regarding which specific lots were affected, failure to remove all impacted product, and stocking products that arrived after the recall notification.\u003C\u002Fp>\u003Cp>On November 20, 2025, FDA held a call with you to discuss the ineffectiveness of the recall within your Albertsons stores. During this discussion, FDA requested information regarding actions you were prepared to implement to ensure recalled product was no longer available for purchase at Albertsons stores nationwide. Despite follow-up emails from the FDA on November 20 and 24, 2025, and December 1 and 8, 2025, you have not provided FDA with any information demonstrating that corrective actions to effectuate this recall have been implemented throughout your organization to prevent adulterated food from being received in interstate commerce and subsequently offered for sale.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with the food you receive and offer for sale at your establishments. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe you are not in violation of the FD&amp;C Act, include your reasoning and any supportive information for our consideration.\u003C\u002Fp>\u003Cp>Please send your reply via email to: HFP-OCE-EmergingIssues@fda.hhs.gov, copying Katherine Arnold, Compliance Officer, at Katherine.Arnold@fda.hhs.gov. If you have any questions regarding any issues in this letter, please contact Katherine Arnold, Compliance Officer, via email at Katherine.Arnold@fda.hhs.gov. Please include CMS reference #720465 on any submissions and within the subject line of any email correspondence to the agency.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Ann M. Oxenham, JD\u003Cbr>Director\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Human Foods Program\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>_______________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As of December 10, 2025, CDC broadened the definition for the outbreak investigation to include any infant with botulism who was exposed to ByHeart infant formula at any time since the product’s release in March 2022.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nSusan Morris\n\nRecipient Title\n\nCEO\n\nThe Albertsons Companies Incorporated\n\nM.S 10501 P.O. Box 29093\n\nPhoenix, AZ 85038\n\nUnited States\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nDecember 12, 2025\nWARNING LETTER\nCMS #720465\nDear Ms. Morris:\nBeginning in November 2025, the U.S. Food and Drug Administration (FDA), in collaboration with the Centers for Disease Control and Prevention (CDC), the California Department of Public Health (CDPH), Infant Botulism Treatment and Prevention Program (IBTPP), and state and local partners, has been investigating a multistate outbreak of infant botulism linked to ByHeart Whole Nutrition Infant Formula. As of December 10, 2025, CDC reported that 51 infants from 19 states have suspected or confirmed infant botulism.1 Infants range from 16 to 264 days of age. Based on epidemiological evidence, CDC has determined that ByHeart Whole Nutrition Infant Formula was the source of this multistate infant botulism outbreak.\nThe presence of Clostridium botulinum in ByHeart Whole Nutrition Infant Formula, as evidenced by the recent foodborne outbreak, causes these products to be adulterated within the meaning of section 402(a)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. § 342(a)(1)] in that they bear or contain an added poisonous or deleterious substance which may render them injurious to health.\nOn November 8, 2025, ByHeart Inc. (ByHeart) initiated a voluntary recall of (b)(4) lots of its ByHeart Whole Nutrition Infant Formula. As a consignee of the recalled products, The Albertsons Companies Incorporated (Albertsons) was notified in writing on November 8, 2025, of this voluntary recall. On November 11, 2025, ByHeart expanded the recall to all ByHeart Whole Nutrition Infant Formula, including all unexpired lots of formula cans and single-serve “anywhere pack” sticks. Albertsons was notified in writing on November 11, 2025, that the scope of the voluntary recall had expanded to include all ByHeart infant formula products. Despite these recall notifications, subsequent visits by regulators confirmed that recalled ByHeart Whole Nutrition Infant Formula remained available for purchase on shelves at (b)(4) Albertsons stores, including Albertson’s, Star Market, Jewel-Osco, Acme, Safeway, and Shaw’s, across 11 states well after the recall was initiated and subsequently expanded. The receipt in interstate commerce of adulterated food, and the delivery or proffered delivery thereof for pay or otherwise, is a violation of section 301(c) of the FD&C Act [21 U.S.C. § 331(c)]. You can find the FD&C Act and its implementing regulations through links on FDA’s home page at https:\u002F\u002Fwww.fda.gov.\nInfant Botulism Investigation\nInfants can develop infant botulism when a baby swallows Clostridium botulinum spores that grow in the immature gut and produce toxin. Most infants with infant botulism will initially develop constipation, poor feeding, loss of head control, and difficulty swallowing, which can progress to difficulty breathing and respiratory arrest. Symptoms of infant botulism, which is diagnosed clinically, can take as long as several weeks to develop following formula ingestion.\nState and local public health officials are interviewing caregivers about the foods their infants consumed during the month prior to illness onset. All 51 previously reported infant botulism cases were infants who had been fed ByHeart Whole Nutrition Infant Formula before becoming sick.\nAs part of its onsite inspections, FDA collected and is currently analyzing unopened product samples. This analysis is ongoing, and results will be shared as they become available. Additional testing by FDA, CDC, and state partners is also underway, with results expected in the coming weeks. Because detection of Clostridium botulinum in infant formula is scientifically complex, a negative test result does not rule out the presence of the bacteria in the product.\nReceipt and Offer of Adulterated Foods\nAs noted above, FDA investigators and state and local partners reported that recalled ByHeart formula continued to be found on Albertsons store shelves in multiple locations across multiple states. FDA and state partners have worked with retailers to ensure an effective recall and immediate removal of these products from all store shelves nationwide. All ByHeart infant formula products have been recalled, including all formula cans and single-serve “anywhere pack” sticks, and these products must not be available for sale in stores or online. The receipt in interstate commerce of adulterated food, and the delivery or proffered delivery thereof, is a violation of section 301(c) of the FD&C Act [21 U.S.C. § 331(c)].\nAs a participant in the supply chain, your firm should take prompt and effective action when notified of a product recall. Once your firm has been made aware of a recall or potential safety issue, you should take action to immediately remove the affected product from distribution and sale, cease all further shipment or use, and implement all necessary measures to prevent further exposure to consumers or downstream distribution.\nHowever, based on FDA’s review of information from state and local partners, the Agency determined that recalled ByHeart Whole Nutrition Infant Formula remained on shelves at (b)(4) Albertsons store locations across 11 states from November 12 to November 19, 2025. This represents a period of (b)(4) days after Albertsons was first notified of the initial recall and (b)(4) days after Albertsons was notified of the recall expansion. State and local partners reported several explanations offered by Albertsons store associates for the continued presence of the recalled product, including lack of awareness of the recall notice, confusion regarding which specific lots were affected, failure to remove all impacted product, and stocking products that arrived after the recall notification.\nOn November 20, 2025, FDA held a call with you to discuss the ineffectiveness of the recall within your Albertsons stores. During this discussion, FDA requested information regarding actions you were prepared to implement to ensure recalled product was no longer available for purchase at Albertsons stores nationwide. Despite follow-up emails from the FDA on November 20 and 24, 2025, and December 1 and 8, 2025, you have not provided FDA with any information demonstrating that corrective actions to effectuate this recall have been implemented throughout your organization to prevent adulterated food from being received in interstate commerce and subsequently offered for sale.\nConclusion\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with the food you receive and offer for sale at your establishments. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action, including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe you are not in violation of the FD&C Act, include your reasoning and any supportive information for our consideration.\nPlease send your reply via email to: HFP-OCE-EmergingIssues@fda.hhs.gov, copying Katherine Arnold, Compliance Officer, at Katherine.Arnold@fda.hhs.gov. If you have any questions regarding any issues in this letter, please contact Katherine Arnold, Compliance Officer, via email at Katherine.Arnold@fda.hhs.gov. Please include CMS reference #720465 on any submissions and within the subject line of any email correspondence to the agency.\nSincerely,\n\u002FS\u002F\nAnn M. Oxenham, JD\nDirector\nOffice of Compliance and Enforcement\nHuman Foods Program\nU.S. Food and Drug Administration\n_______________________________\n1 As of December 10, 2025, CDC broadened the definition for the outbreak investigation to include any infant with botulism who was exposed to ByHeart infant formula at any time since the product’s release in March 2022.","The Albertsons Companies Incorporated","albertsons-companies-incorporated-720465-12122025","2026-08-18T06:42:28.498414+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Falbertsons-companies-incorporated-720465-12122025","2026-10-26T08:07:52.119741+00:00","Warning Letter","Issued","2025-12-15","720465","Food & Beverages","Susan Morris","2026-08-19T16:09:45.149+00:00","VIA Electronic Mail","2025-12-12",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":19,"body_fetched_at":49,"delivery_method":50,"recipient_title":19,"reference_number":51,"action_taken_date":52,"medical_device_id":19,"response_letter_date":19},970,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2025-04-08T04:00:00Z\">04\u002F08\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-04-04T04:00:00Z\">04\u002F04\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fthecompanymfgcom-705739-04042025\">thecompanymfg.com\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>RW2502275\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>thecompanymfg.com\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1733 Monrovia Avenue, Suite F\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Costa Mesa\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92627\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:orders@thecompanymfg.com\"> orders@thecompanymfg.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:rich@crumbzvapor.com\"> rich@crumbzvapor.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>April 4, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>To Whom It May Concern:\u003C\u002Fp>\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fthecompanymfg.com and determined that e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that you manufacture and offer for sale or distribution to customers in the United States e-liquid products that lack a marketing authorization order, including: Flakey French by Crumbz and Pear Parfait by Crumbz.\u003C\u002Fp>\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\u003Cp>For a list of all products that have been authorized by the FDA and certain others that may be legally marketed, please visit the Searchable Tobacco Products Database: www.fda.gov\u002Fsearchtobacco.\u003C\u002Fp>\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to adequately address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\u003Cp>Please note your reference number, RW2502275, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement&nbsp;&nbsp;\u003Cbr>FDA Center for Tobacco Products&nbsp;&nbsp;\u003Cbr>c\u002Fo Document Control Center&nbsp;&nbsp;\u003Cbr>Building 71, Room G335&nbsp;&nbsp;\u003Cbr>10903 New Hampshire Avenue&nbsp;&nbsp;\u003Cbr>Silver Spring, MD 20993-0002\u003C\u002Fp>\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>John E. Verbeten\u003Cbr>Director\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Center for Tobacco Products\u003C\u002Fp>\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>cc:\u003C\u002Fp>\u003Cp>The Company MFG\u002FDel Ocho\u002FCrumbz Vapor\u003Cbr>Attn: Shane Simpson and Richard D’Alessio\u003Cbr>155 W Washington Blvd Ste 201\u003Cbr>Los Angeles, CA 90015\u003C\u002Fp>\u003Cp>The Company LLC\u003Cbr>Shane Simpson\u003Cbr>13222 Admiral Ave #B\u003Cbr>Marina Del Rey, CA 90292\u003C\u002Fp>\u003Cp>C3vaporsdistro\u003Cbr>1779 Newport Blvd FL 2\u003Cbr>Costa Mesa, California 92627\u003C\u002Fp>\u003Cp>C3 Vapors &amp; Coffee\u003Cbr>Attn: Richard D’ Alessio\u003Cbr>1777 Newport Blvd\u003Cbr>Costa Mesa, CA 92627\u003C\u002Fp>\u003Cp>OC Elixir, LLC\u003Cbr>440 Fair Dr Ste 200\u003Cbr>Costa Mesa, CA 92626-6222\u003C\u002Fp>\u003Cp>The Company MFG\u003Cbr>Attn: Shane R. Simpson\u003Cbr>Saturn@C3Vapors.com\u003C\u002Fp>\u003Cp>GoDaddy.com, LLC\u003Cbr>abuse@godaddy.com\u003C\u002Fp>\u003Cp>Shopify, Inc.\u003Cbr>abuse@shopify.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nRW2502275\n\nProduct:\n\nTobacco\n\nRecipient:\n\nthecompanymfg.com\n\n1733 Monrovia Avenue, Suite F\n\nCosta Mesa, CA 92627\n\nUnited States\n\norders@thecompanymfg.com\n\nrich@crumbzvapor.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nApril 4, 2025\nWARNING LETTER\nTo Whom It May Concern:\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fthecompanymfg.com and determined that e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\nFDA has determined that you manufacture and offer for sale or distribution to customers in the United States e-liquid products that lack a marketing authorization order, including: Flakey French by Crumbz and Pear Parfait by Crumbz.\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)).\nConclusion and Requested Actions\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\nFor a list of all products that have been authorized by the FDA and certain others that may be legally marketed, please visit the Searchable Tobacco Products Database: www.fda.gov\u002Fsearchtobacco.\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to adequately address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\nPlease note your reference number, RW2502275, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\nDPAL-WL Response, Office of Compliance and Enforcement\nFDA Center for Tobacco Products\nc\u002Fo Document Control Center\nBuilding 71, Room G335\n10903 New Hampshire Avenue\nSilver Spring, MD 20993-0002\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nJohn E. Verbeten\nDirector\nOffice of Compliance and Enforcement\nCenter for Tobacco Products\nVIA UPS and Electronic Mail\ncc:\nThe Company MFG\u002FDel Ocho\u002FCrumbz Vapor\nAttn: Shane Simpson and Richard D’Alessio\n155 W Washington Blvd Ste 201\nLos Angeles, CA 90015\nThe Company LLC\nShane Simpson\n13222 Admiral Ave #B\nMarina Del Rey, CA 90292\nC3vaporsdistro\n1779 Newport Blvd FL 2\nCosta Mesa, California 92627\nC3 Vapors & Coffee\nAttn: Richard D’ Alessio\n1777 Newport Blvd\nCosta Mesa, CA 92627\nOC Elixir, LLC\n440 Fair Dr Ste 200\nCosta Mesa, CA 92626-6222\nThe Company MFG\nAttn: Shane R. Simpson\nSaturn@C3Vapors.com\nGoDaddy.com, LLC\nabuse@godaddy.com\nShopify, Inc.\nabuse@shopify.com","thecompanymfg.com","thecompanymfgcom-705739-04042025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fthecompanymfgcom-705739-04042025","2026-10-26T08:10:11.107751+00:00","2025-04-08","705739","Tobacco","2026-08-19T16:53:27.954+00:00","VIA UPS and Electronic Mail","RW2502275","2025-04-04",{"id":54,"raw":55,"subject":60,"body_html":61,"body_text":62,"firm_name":63,"letter_id":64,"created_at":65,"fei_number":19,"letter_url":66,"updated_at":67,"action_type":22,"case_status":23,"posted_date":68,"marcs_cms_no":69,"product_type":70,"closeout_date":19,"issuing_office":59,"recipient_name":71,"body_fetched_at":72,"delivery_method":73,"recipient_title":19,"reference_number":74,"action_taken_date":75,"medical_device_id":19,"response_letter_date":19},21646,[56,57,58,59,60,13,13,13],"\u003Ctime datetime=\"2026-08-25T04:00:00Z\">08\u002F25\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-08-14T04:00:00Z\">08\u002F14\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fr3-medical-companies-726330-08142026\">R3 Medical Companies\u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","Unapproved New Drugs\u002FUnlicensed Biological Product Violations","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via UPS and EMAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 26-726330\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>David L. Greene, M.D.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>R3 Medical Companies\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>10045 E. Dynamite Blvd., Suite 260\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Scottsdale\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85262\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:dgreene@bello.bio\"> dgreene@bello.bio\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:dgreene@regensuppliers.com\"> dgreene@regensuppliers.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>August 14, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>CBER 26-726330\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Dr. Greene:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your facilities, Bello Bio, LLC (herein referred to as “Bello”) and Regen Suppliers, LLC (herein referred to as “Regen”) co-located at 10045 E. Dynamite Blvd., Suite 260, Scottsdale, AZ 85262, between November 17, 2025, and December 16, 2025.\u003Cem>\u003Cstrong>\u003Csup>1,2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> During the inspections, FDA documented that Bello contract manufactures and labels umbilical cord derived products, ReBellaWJ, ReBellaXO, and ReBellaXOL, for private label distribution by Regen.\u003Cem>\u003Cstrong>\u003Csup>3,4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Regen approves, labels, stores, and distributes the aforementioned products as well as an umbilical cord blood derived product, ReBellaCB, contract manufactured under private label by \u003Cstrong>(b)(4)\u003C\u002Fstrong> ReBellaWJ, ReBellaXO, and ReBellaXOL will herein be referred to as “your umbilical cord derived products.” These three products, together with ReBellaCB, will be referred to collectively as “your products.”\u003C\u002Fp>\u003Cp>This letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Your products are also unlicensed biological products in violation of section 351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&amp;C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act. Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. § 331(d).\u003C\u002Fp>\u003Cp>This warning letter also summarizes significant violations of current good manufacturing practice (CGMP) requirements, including violations of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. § 351(a)(2)(B), and 21 CFR parts 210 and 211, in the manufacture of your products. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding drugs do not conform to CGMP, your products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. § 351(a)(2)(B). Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is a prohibited act under section 301(a) of the FD&amp;C Act, 21 U.S.C. § 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug and Unlicensed Biological Product Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on information and records reviewed by FDA, including, but not limited to, your YouTube channel, @R3StemCell www.youtube.com\u002F@R3StemCell, TikTok @R3StemCell www.tiktok.com\u002F@r3stemcell, Instagram @R3stemcellofficial, www.instagram.com\u002Fr3stemcellofficial, Facebook page R3 Stem Cell www.facebook.com\u002Fr3stemcelltherapyofficial, and websites, www.r3stemcell.com, www.bello.bio, and www.regensuppliers.com5, (last visited August 2026), your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans, and\u002For are intended to affect the structure or function of the body. For example:\u003C\u002Fp>\u003Cul>\u003Cli>ReBellaWJ:\u003Cbr>o R3 Stem Cell, LLC website (www.r3stemcell.com\u002F):\u003Cbr> In a November 15, 2020, blog post entitled “\u003Cem>What is Umbilical Cord Wharton’s Jelly\u003C\u002Fem>?” (https:\u002F\u002Fr3stemcell.com\u002Fwhat-is-umbilical-cord-whartons-jelly\u002F):\u003Cbr>• “One of the major effects is the reduction of inflammation. Chronic inflammation has been shown to be present in the body and is a known precursor to many medical conditions including organ failure, arthritis, several types of cancer and more. The biologic’s cells are able to systemically reduce this inflammation…”\u003Cbr>• “…The top wharton’s jelly stem cell product being offered is ReBellaWJ…To find out more information and to place an order, visit and call Regen Suppliers at (888) 568-6909.”\u003Cbr> Under a title of “What conditions benefit from their use?” on Umbilical Cord Stem Cell Therapy tab: “In the research literature and from our provider’s experience, there are benefits being shown for: Neurologic Conditions…Heart\u002FKidney\u002FLung Failure (e.g. Cardiomyopathy, COPD)…Autism…Cerebral Palsy…Diabetes…Lyme Disease...SI Joint Pain...Erectile Dysfunction..”\u003Cbr>o R3 Anti-Aging website (https:\u002F\u002Fr3antiaging.com):\u003Cbr> Under the “Umbilical Cord Allograft” tab within your “Regenerative Therapies” page: “R3 Anti-Aging and Medspa in Scottsdale and Nashville offers umbilical cord allograft therapy for patients who have joint or soft tissue pain...In addition, the umbilical cord tissue contains a significant amount of growth factors, exosomes, mesenchymal stem cells and cytokines as well. These facilitate one's body to amp up the repair and regeneration activities to reduce pain from joint degeneration, tendonitis, bursitis...and neuropathy.”\u003C\u002Fli>\u003Cli>ReBellaXO and ReBellaXOL:\u003Cbr>o Regen website (https:\u002F\u002Fwww.regensuppliers.com):\u003Cbr> Until recently, within the “ReBellaXO 1.0mL - B” product page: “ReBellaXO an exosome allograft derived from Wharton's Jelly MSCs... For your procedures involving IV's, joints, soft tissue, hair, facial or sexual rejuvenation, ReBellaXO represents your most cost effective and safe option for fitting regenerative biologics into your patient care!”\u003Cbr> Until recently, under the “About” tab: “ReBellaXOL Lyophilized Exosomes… produces collagenesis, anti-scar, pro-angiogenesis, &amp; anti-apoptosis. BelloXO intensely stimulates regeneration…”\u003Cbr>o R3 Stem Cell, LLC website (www.r3stemcell.com\u002F):\u003Cbr> Under the Exosome Therapy tab: “Can exosomes help with neurodegenerative conditions? Research has shown that exosomes can penetrate the blood-brain barrier and stimulate neuronal differentiation, growth of neurons, and reduce inflammatory processes within the brain tissue. This may result in future benefit to neurodegenerative conditions such as Alzheimer’s, Parkinson’s, Post Stroke and other issues.”\u003Cbr>o R3 Anti-Aging website (https:\u002F\u002Fr3antiaging.com):\u003Cbr> The \"Exosome therapy\" page within your \"Treatments\" tab under \"Regenerative Therapies,\"\u003Cbr>• “Exosome Therapy for Joint Pain… Exosome therapy is getting great results for joint pain relief:… Rebuilding cartilage: Exosomes help fix damaged cartilage… Reducing inflammation: They calm the swelling in your joints.”\u003Cbr>• Listing “Wound Healing” and “Anti-Inflammation” in a chart titled “Benefits of Exosome Therapy”\u003C\u002Fli>\u003Cli>ReBellaCB:\u003Cbr>o Until recently, the product page for ReBellaCB on your Regen website, (www.regensuppliers.com), states, “REBELLACB is an Umbilical Cord Blood Stem Cell Allograft” and links to an R3 Stem Cell YouTube video, https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=sZeux0WXsUU&amp;feature=youtu.be, titled “\u003Cem>Is Umbilical Cord Blood Safe for Regenerative Procedures?\u003C\u002Fem>” with the video description stating, “For years now, umbilical cord blood has been used increasingly for non-malignant conditions such as arthritis, neurological conditions, autism, diabetes, liver\u002Fkidney failure and much more. Umbilical cord tissue has a ton of hematopoietic and mesenchymal stem cells along with cytokines, growth factors, and exosomes. All of this makes it very effective for these conditions.”\u003C\u002Fli>\u003Cli>ReBellaCB and ReBellaXO:\u003Cbr>o In a video posted on your R3 Stem Cell YouTube Channel on March 5, 2026 (https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=L0QlPvhdjds) titled “\u003Cem>Elite Football Player Talks to His Stem Cells (844) GET-STEM\u003C\u002Fem>,” an employee is seen showing vials of ReBellaCB and ReBellaXO to a patient and states: “These are your stem cells. There’s 30 million in each vial... This is ReBellaXO. These are your exosomes… Those are very anti-inflammatory...” [0.00-0.24] so should help a lot…” The video description states, “When receiving stem cell therapy to help with injuries, athletes should talk to their cells.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Therefore, your products are drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\u003C\u002Fp>\u003Cp>Your ReBellaWJ, ReBellaXO, ReBellaXOL, and ReBellaCB products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, your firm does not qualify for any exception in 21 CFR 1271.15, and your products fail to meet all criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\u003Cp>For example, your ReBellaWJ, ReBellaXO, ReBellaXOL and ReBellaCB products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only.” Homologous use means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor” (21 CFR 1271.3(c) and 1271.10(a)(2)). Your products are not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit for umbilical cord or forming and replenishing the lymphohematopoietic system for umbilical cord blood). Rather, your products are intended for use in the treatment of various diseases and conditions, such as, but not limited to, arthritis and inflammation, which is not a basic function of umbilical cord or umbilical cord blood in the donor.\u003C\u002Fp>\u003Cp>Moreover, your ReBellaCB product fails to meet the criterion in 21 CFR 1271.10(a)(4) because it is manufactured from allogeneic umbilical cord blood, is dependent on the metabolic activity of living cells for its primary function, and is not for autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use.\u003C\u002Fp>\u003Cp>Therefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.6 See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your products are regulated as drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\u003C\u002Fp>\u003Cp>Subject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA’s inspections of your Bello and Regen facilities documented evidence of significant CGMP violations. At the conclusion of the inspections, FDA investigators issued a Form FDA-483, List of Inspectional Observations (Form FDA-483), to each of Bello and Regen. FDA also identified additional significant violations upon further review of the evidence collected during the inspection, as set forth below.\u003C\u002Fp>\u003Cp>The CGMP violations applicable to your Bello facility pertaining to your umbilical cord derived products include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes, as required by 21 CFR 211.113(b).\u003C\u002Fstrong> For example, your firm has not validated the aseptic processes used to manufacture your umbilical cord derived products. Your umbilical cord derived products purport to be sterile and are expected to be sterile.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity that they are purported or represented to possess, as required by 21 CFR 211.100(a).\u003C\u002Fstrong> For example, your firm has not validated the manufacturing processes for your umbilical cord derived products with respect to identity, strength, quality, and purity.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Failure to establish laboratory controls that include scientifically sound and appropriate specifications, standards, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity, as required by 21 CFR 211.160(b).\u003C\u002Fstrong> For example, samples of your umbilical cord derived products are frozen and thawed prior to sterility testing. Freezing samples has the potential to destroy or compromise any microbial content in the samples before testing, if present; therefore, any contamination that was present prior to freezing may not be reliably detected.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions, as required by 21 CFR 211.42(c)(10)(v).\u003C\u002Fstrong> For example, you have not validated your processes for cleaning and disinfecting the ISO \u003Cstrong>(b)(4)\u003C\u002Fstrong> biological safety cabinet (BSC) where your products are exposed to the environment during aseptic processing.\u003C\u002Fp>\u003Cp>\u003Cstrong>5. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use results of such stability testing to determine appropriate storage conditions and expiration dates, as required by 21 CFR 211.166(a).\u003C\u002Fstrong> For example, your firm assigns a 24-month expiration date to your products without supporting stability testing data.\u003C\u002Fp>\u003Cp>The CGMP violations applicable to your Bello and Regen facilities pertaining to your products include, but are not limited to, the following:\u003Cem>\u003Cstrong>\u003Csup>7\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>\u003Cstrong>6. The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed, as required by 21 CFR 211.22(d).\u003C\u002Fstrong> For example, at the time of the inspection, written procedures describing the responsibilities of the quality unit had not been established, including but not limited to, procedures for the approval or rejection of drug products (21 CFR 211.22(a)) and the handling of all written and oral complaints regarding a drug product (21 CFR 211.198(a)).\u003C\u002Fp>\u003Cp>\u003Cstrong>Responses to the Form FDA-483\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We have reviewed your responses to the Form FDA-483s issued to each of your Bello and Regen facilities dated January 08, 2026 and January 06, 2026, as well as your correspondence dated November 20, 2025, in detail. While you represented that you have implemented or plan to implement certain corrective actions, the described corrective actions are not adequate to remedy the violations noted above. For example, your responses do not address your continued distribution of your products or specific plans for disposition of the remaining inventory manufactured under the violative conditions outlined above. We note that certain corrective actions cannot be evaluated because they lack supporting documentation.\u003C\u002Fp>\u003Cp>Further, for your previously distributed products, you do not describe actions you have taken or plan to take that adequately address the impact of the above-noted deficiencies on your distributed products that are still within expiry and were manufactured under the above-described violative conditions.\u003C\u002Fp>\u003Cp>We acknowledge your commitment to temporarily suspend manufacturing operations until you have made corrections to the observations listed on the Form FDA-483 issued to each of your Bello and Regen facilities. However, this does not resolve the violations outlined in this letter because your responses do not adequately address your failure to have an Investigational New Drug (IND) in effect to study your products addressed in this letter or your lack of an approved BLA to lawfully market your products.\u003C\u002Fp>\u003Cp>FDA has previously provided notice to you, David Greene, in a letter dated May 28, 2019, that based on a review of your website for R3 Stem Cell, LLC (www.r3stemcell.com) at that time, your firm appeared to offer “regenerative stem cell therapies” while promoting these stem cell therapies for numerous diseases or conditions, such as amyotrophic lateral sclerosis (ALS), diabetes, kidney failure, Lyme disease, Parkinson’s disease, and stroke. Based on that review, R3 Stem Cell, LLC did not appear to qualify for any exception under 21 CFR 1271.15; the “regenerative stem cell therapies” were intended for nonhomologous uses and thus would be regulated as drugs as defined in section 201(g) of the FD&amp;C Act [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the PHS Act [42 U.S.C. 262(i)]. However, our review of your current websites and various social media accounts, which are also linked to your websites, indicates umbilical stem cell therapy and exosome therapy continue to be offered by R3 Stem Cell, LLC for treatment of various diseases and conditions, as described above.\u003C\u002Fp>\u003Cp>\u003Cstrong>Additional Concerns\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition to the violations described above, we have the following concerns:\u003C\u002Fp>\u003Cul>\u003Cli>FDA’s review of information and records collected during the inspections documented Bello also manufactures the following umbilical cord derived\u003Cem>\u003Cstrong>\u003Csup>8\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> products: BelloWJ, BelloXO, and BelloXOL. Your response dated January 08, 2026 asserts that Bello is a manufacturer of HCT\u002FPs and is subject only to current good tissue practice (CGTP) requirements of 21 CFR Part 1271 and is regulated solely under section 361 of the PHS Act); however, review of the evidence collected shows these products do not appear to meet the relevant criteria to be regulated solely under section 361 of the PHS Act, for the reasons discussed above. These products appear to be drugs and\u002For biological products, which are subject to premarket review and approval requirements.\u003C\u002Fli>\u003Cli>FDA review of Bello’s manufacturing records revealed that \u003Cstrong>(b)(4)\u003C\u002Fstrong> is a component of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> used during Bello’s manufacturing process of products derived from umbilical cord tissue; however, there did not appear to be evidence that testing for \u003Cstrong>(b)(4)\u003C\u002Fstrong> had been performed prior to the release of these products, as required by \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>Bello determines donor eligibility upon review of relevant medical records per your contract agreement with \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The “\u003Cem>Donor Eligibility Criteria\u003C\u002Fem>” documents (effective date 08\u002F15\u002F2023) submitted with your January 8, 2026, response and also collected during the inspection do not include “qualifiers\u002Fcomments” for Transmissible Spongiform Encephalopathy (TSE). In accordance with 21 CFR 1271.75(a)(1)(iv), all donors of cells or tissues, except as provided under 1271.90, must be screened by reviewing the donor’s relevant medical records for risk factors for, and clinical evidence of, relevant communicable disease agents and diseases, including human transmissible spongiform encephalopathy, including Creutzfeldt-Jakob disease. Additionally, FDA Guidance for Industry: \u003Cem>Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products\u003C\u002Fem> (August 2007)\u003Cem>\u003Cstrong>\u003Csup>9\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> recommends screening donors for TSE, including Creutzfeldt-Jakob disease (CJD) and variant CJD (vCJD), by asking if donors have been diagnosed with dementia or any degenerative or demyelinating diseases of the central nervous system or other neurological disease of unknown etiology. For additional information and recommendations intended to assist establishments with complying with all requirements in 21 CFR part 1271, subpart C, please refer to the guidance.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Neither this letter nor the observations noted on the Form FDA-483s for both Bello and Regen, which were discussed with you at the conclusion of the inspections, are intended to be all-inclusive lists of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>Please submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Vincent Amatrudo\u003Cbr>Acting Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>Cc: \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> During the inspections, you informed FDA that R3 Medical Companies is the parent company of these companies co-located at the same business address: Bello, Regen, R3 Stem Cell, LLC and R3 Anti-Aging Scottsdale LLC. You bear primary responsibility for the business operations at each of the aforementioned entities.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Greene Technologies, LLC, for which you are the co-owner and majority holder, along with Ms. Deborah Greene, invests in the referenced entities and other R3 Anti-Aging LLC clinics located at 5020 Thoroughbred Lane, Brentwood, TN 37027 and 9301 Wilshire Boulevard Penthouse, Beverly Hills, CA 90210. The referenced entities function together with Bello as the manufacturer and Regen as the private label distributor to the three R3 Anti-Aging clinics, healthcare professionals, and other clinics as direct-to-customers and through R3 Stem Cell’s partnership program, R3 Alliance Partner. We note you are also the current Chief Executive Officer (CEO) of R3 Anti-Aging &amp; MedSpa Nashville, LLC (located at 5020 Thoroughbred Lane, Brentwood, TN 37027) and R3 Anti-Aging Beverly Hills, LLC (located at 9301 Wilshire Boulevard Penthouse, Beverly Hills, CA 90210).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Regen markets ReBellaXO and ReBellaXOL as exosome products; however, products manufactured by Bello use the same starting material and manufacturing process (with the exception of an added lyophilization step for ReBellaXOL), which does not appear would isolate exosomes.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> ReBellaXOL was also labeled as ReBellaGF by Bello at the time of the inspections.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> As of August 14, 2026, it appears that the Regen Suppliers website www.regensuppliers.com is no longer accessible with a “404, Not Found.” message displayed.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> Because your products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a) for each product.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem> Although products are contract manufactured for Regen, Regen’s activities, as described above, constitute manufacturing under 21 CFR 210.3(b)(12). Regen is therefore subject to CGMP requirements.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>8\u003C\u002Fstrong>\u003C\u002Fem> Bello markets BelloXO and BelloXOL as exosome products; however, it does not appear that the manufacturing process would isolate exosomes.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>9\u003C\u002Fstrong>\u003C\u002Fem> See https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Feligibility-determination-donors-human-cells-tissues-and-cellular-and-tissue-based-products.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia UPS and EMAIL\n\nReference #:\n\nCBER 26-726330\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nDavid L. Greene, M.D.\n\nRecipient Title\n\nChief Executive Officer\n\nR3 Medical Companies\n\n10045 E. Dynamite Blvd., Suite 260\n\nScottsdale, AZ 85262\n\nUnited States\n\ndgreene@bello.bio\n\ndgreene@regensuppliers.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\nAugust 14, 2026\nCBER 26-726330\nDear Dr. Greene:\nThe United States Food and Drug Administration (FDA) inspected your facilities, Bello Bio, LLC (herein referred to as “Bello”) and Regen Suppliers, LLC (herein referred to as “Regen”) co-located at 10045 E. Dynamite Blvd., Suite 260, Scottsdale, AZ 85262, between November 17, 2025, and December 16, 2025.1,2 During the inspections, FDA documented that Bello contract manufactures and labels umbilical cord derived products, ReBellaWJ, ReBellaXO, and ReBellaXOL, for private label distribution by Regen.3,4 Regen approves, labels, stores, and distributes the aforementioned products as well as an umbilical cord blood derived product, ReBellaCB, contract manufactured under private label by (b)(4) ReBellaWJ, ReBellaXO, and ReBellaXOL will herein be referred to as “your umbilical cord derived products.” These three products, together with ReBellaCB, will be referred to collectively as “your products.”\nThis letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Your products are also unlicensed biological products in violation of section 351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act. Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. § 331(d).\nThis warning letter also summarizes significant violations of current good manufacturing practice (CGMP) requirements, including violations of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. § 351(a)(2)(B), and 21 CFR parts 210 and 211, in the manufacture of your products. Because your methods, facilities, or controls for manufacturing, processing, packing, or holding drugs do not conform to CGMP, your products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. § 351(a)(2)(B). Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is a prohibited act under section 301(a) of the FD&C Act, 21 U.S.C. § 331(a).\nUnapproved New Drug and Unlicensed Biological Product Violations\nBased on information and records reviewed by FDA, including, but not limited to, your YouTube channel, @R3StemCell www.youtube.com\u002F@R3StemCell, TikTok @R3StemCell www.tiktok.com\u002F@r3stemcell, Instagram @R3stemcellofficial, www.instagram.com\u002Fr3stemcellofficial, Facebook page R3 Stem Cell www.facebook.com\u002Fr3stemcelltherapyofficial, and websites, www.r3stemcell.com, www.bello.bio, and www.regensuppliers.com5, (last visited August 2026), your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans, and\u002For are intended to affect the structure or function of the body. For example:\nReBellaWJ:\no R3 Stem Cell, LLC website (www.r3stemcell.com\u002F):\n In a November 15, 2020, blog post entitled “What is Umbilical Cord Wharton’s Jelly?” (https:\u002F\u002Fr3stemcell.com\u002Fwhat-is-umbilical-cord-whartons-jelly\u002F):\n• “One of the major effects is the reduction of inflammation. Chronic inflammation has been shown to be present in the body and is a known precursor to many medical conditions including organ failure, arthritis, several types of cancer and more. The biologic’s cells are able to systemically reduce this inflammation…”\n• “…The top wharton’s jelly stem cell product being offered is ReBellaWJ…To find out more information and to place an order, visit and call Regen Suppliers at (888) 568-6909.”\n Under a title of “What conditions benefit from their use?” on Umbilical Cord Stem Cell Therapy tab: “In the research literature and from our provider’s experience, there are benefits being shown for: Neurologic Conditions…Heart\u002FKidney\u002FLung Failure (e.g. Cardiomyopathy, COPD)…Autism…Cerebral Palsy…Diabetes…Lyme Disease...SI Joint Pain...Erectile Dysfunction..”\no R3 Anti-Aging website (https:\u002F\u002Fr3antiaging.com):\n Under the “Umbilical Cord Allograft” tab within your “Regenerative Therapies” page: “R3 Anti-Aging and Medspa in Scottsdale and Nashville offers umbilical cord allograft therapy for patients who have joint or soft tissue pain...In addition, the umbilical cord tissue contains a significant amount of growth factors, exosomes, mesenchymal stem cells and cytokines as well. These facilitate one's body to amp up the repair and regeneration activities to reduce pain from joint degeneration, tendonitis, bursitis...and neuropathy.”\nReBellaXO and ReBellaXOL:\no Regen website (https:\u002F\u002Fwww.regensuppliers.com):\n Until recently, within the “ReBellaXO 1.0mL - B” product page: “ReBellaXO an exosome allograft derived from Wharton's Jelly MSCs... For your procedures involving IV's, joints, soft tissue, hair, facial or sexual rejuvenation, ReBellaXO represents your most cost effective and safe option for fitting regenerative biologics into your patient care!”\n Until recently, under the “About” tab: “ReBellaXOL Lyophilized Exosomes… produces collagenesis, anti-scar, pro-angiogenesis, & anti-apoptosis. BelloXO intensely stimulates regeneration…”\no R3 Stem Cell, LLC website (www.r3stemcell.com\u002F):\n Under the Exosome Therapy tab: “Can exosomes help with neurodegenerative conditions? Research has shown that exosomes can penetrate the blood-brain barrier and stimulate neuronal differentiation, growth of neurons, and reduce inflammatory processes within the brain tissue. This may result in future benefit to neurodegenerative conditions such as Alzheimer’s, Parkinson’s, Post Stroke and other issues.”\no R3 Anti-Aging website (https:\u002F\u002Fr3antiaging.com):\n The \"Exosome therapy\" page within your \"Treatments\" tab under \"Regenerative Therapies,\"\n• “Exosome Therapy for Joint Pain… Exosome therapy is getting great results for joint pain relief:… Rebuilding cartilage: Exosomes help fix damaged cartilage… Reducing inflammation: They calm the swelling in your joints.”\n• Listing “Wound Healing” and “Anti-Inflammation” in a chart titled “Benefits of Exosome Therapy”\nReBellaCB:\no Until recently, the product page for ReBellaCB on your Regen website, (www.regensuppliers.com), states, “REBELLACB is an Umbilical Cord Blood Stem Cell Allograft” and links to an R3 Stem Cell YouTube video, https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=sZeux0WXsUU&feature=youtu.be, titled “Is Umbilical Cord Blood Safe for Regenerative Procedures?” with the video description stating, “For years now, umbilical cord blood has been used increasingly for non-malignant conditions such as arthritis, neurological conditions, autism, diabetes, liver\u002Fkidney failure and much more. Umbilical cord tissue has a ton of hematopoietic and mesenchymal stem cells along with cytokines, growth factors, and exosomes. All of this makes it very effective for these conditions.”\nReBellaCB and ReBellaXO:\no In a video posted on your R3 Stem Cell YouTube Channel on March 5, 2026 (https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=L0QlPvhdjds) titled “Elite Football Player Talks to His Stem Cells (844) GET-STEM,” an employee is seen showing vials of ReBellaCB and ReBellaXO to a patient and states: “These are your stem cells. There’s 30 million in each vial... This is ReBellaXO. These are your exosomes… Those are very anti-inflammatory...” [0.00-0.24] so should help a lot…” The video description states, “When receiving stem cell therapy to help with injuries, athletes should talk to their cells.”\nTherefore, your products are drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\nYour ReBellaWJ, ReBellaXO, ReBellaXOL, and ReBellaCB products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, your firm does not qualify for any exception in 21 CFR 1271.15, and your products fail to meet all criteria in 21 CFR 1271.10(a).\nFor example, your ReBellaWJ, ReBellaXO, ReBellaXOL and ReBellaCB products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only.” Homologous use means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor” (21 CFR 1271.3(c) and 1271.10(a)(2)). Your products are not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit for umbilical cord or forming and replenishing the lymphohematopoietic system for umbilical cord blood). Rather, your products are intended for use in the treatment of various diseases and conditions, such as, but not limited to, arthritis and inflammation, which is not a basic function of umbilical cord or umbilical cord blood in the donor.\nMoreover, your ReBellaCB product fails to meet the criterion in 21 CFR 1271.10(a)(4) because it is manufactured from allogeneic umbilical cord blood, is dependent on the metabolic activity of living cells for its primary function, and is not for autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use.\nTherefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.6 See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your products are regulated as drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\nSubject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\nCGMP Violations\nFDA’s inspections of your Bello and Regen facilities documented evidence of significant CGMP violations. At the conclusion of the inspections, FDA investigators issued a Form FDA-483, List of Inspectional Observations (Form FDA-483), to each of Bello and Regen. FDA also identified additional significant violations upon further review of the evidence collected during the inspection, as set forth below.\nThe CGMP violations applicable to your Bello facility pertaining to your umbilical cord derived products include, but are not limited to, the following:\n1. Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes, as required by 21 CFR 211.113(b). For example, your firm has not validated the aseptic processes used to manufacture your umbilical cord derived products. Your umbilical cord derived products purport to be sterile and are expected to be sterile.\n2. Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity that they are purported or represented to possess, as required by 21 CFR 211.100(a). For example, your firm has not validated the manufacturing processes for your umbilical cord derived products with respect to identity, strength, quality, and purity.\n3. Failure to establish laboratory controls that include scientifically sound and appropriate specifications, standards, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity, as required by 21 CFR 211.160(b). For example, samples of your umbilical cord derived products are frozen and thawed prior to sterility testing. Freezing samples has the potential to destroy or compromise any microbial content in the samples before testing, if present; therefore, any contamination that was present prior to freezing may not be reliably detected.\n4. Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions, as required by 21 CFR 211.42(c)(10)(v). For example, you have not validated your processes for cleaning and disinfecting the ISO (b)(4) biological safety cabinet (BSC) where your products are exposed to the environment during aseptic processing.\n5. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use results of such stability testing to determine appropriate storage conditions and expiration dates, as required by 21 CFR 211.166(a). For example, your firm assigns a 24-month expiration date to your products without supporting stability testing data.\nThe CGMP violations applicable to your Bello and Regen facilities pertaining to your products include, but are not limited to, the following:7\n6. The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed, as required by 21 CFR 211.22(d). For example, at the time of the inspection, written procedures describing the responsibilities of the quality unit had not been established, including but not limited to, procedures for the approval or rejection of drug products (21 CFR 211.22(a)) and the handling of all written and oral complaints regarding a drug product (21 CFR 211.198(a)).\nResponses to the Form FDA-483\nWe have reviewed your responses to the Form FDA-483s issued to each of your Bello and Regen facilities dated January 08, 2026 and January 06, 2026, as well as your correspondence dated November 20, 2025, in detail. While you represented that you have implemented or plan to implement certain corrective actions, the described corrective actions are not adequate to remedy the violations noted above. For example, your responses do not address your continued distribution of your products or specific plans for disposition of the remaining inventory manufactured under the violative conditions outlined above. We note that certain corrective actions cannot be evaluated because they lack supporting documentation.\nFurther, for your previously distributed products, you do not describe actions you have taken or plan to take that adequately address the impact of the above-noted deficiencies on your distributed products that are still within expiry and were manufactured under the above-described violative conditions.\nWe acknowledge your commitment to temporarily suspend manufacturing operations until you have made corrections to the observations listed on the Form FDA-483 issued to each of your Bello and Regen facilities. However, this does not resolve the violations outlined in this letter because your responses do not adequately address your failure to have an Investigational New Drug (IND) in effect to study your products addressed in this letter or your lack of an approved BLA to lawfully market your products.\nFDA has previously provided notice to you, David Greene, in a letter dated May 28, 2019, that based on a review of your website for R3 Stem Cell, LLC (www.r3stemcell.com) at that time, your firm appeared to offer “regenerative stem cell therapies” while promoting these stem cell therapies for numerous diseases or conditions, such as amyotrophic lateral sclerosis (ALS), diabetes, kidney failure, Lyme disease, Parkinson’s disease, and stroke. Based on that review, R3 Stem Cell, LLC did not appear to qualify for any exception under 21 CFR 1271.15; the “regenerative stem cell therapies” were intended for nonhomologous uses and thus would be regulated as drugs as defined in section 201(g) of the FD&C Act [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the PHS Act [42 U.S.C. 262(i)]. However, our review of your current websites and various social media accounts, which are also linked to your websites, indicates umbilical stem cell therapy and exosome therapy continue to be offered by R3 Stem Cell, LLC for treatment of various diseases and conditions, as described above.\nAdditional Concerns\nIn addition to the violations described above, we have the following concerns:\nFDA’s review of information and records collected during the inspections documented Bello also manufactures the following umbilical cord derived8 products: BelloWJ, BelloXO, and BelloXOL. Your response dated January 08, 2026 asserts that Bello is a manufacturer of HCT\u002FPs and is subject only to current good tissue practice (CGTP) requirements of 21 CFR Part 1271 and is regulated solely under section 361 of the PHS Act); however, review of the evidence collected shows these products do not appear to meet the relevant criteria to be regulated solely under section 361 of the PHS Act, for the reasons discussed above. These products appear to be drugs and\u002For biological products, which are subject to premarket review and approval requirements.\nFDA review of Bello’s manufacturing records revealed that (b)(4) is a component of the (b)(4) used during Bello’s manufacturing process of products derived from umbilical cord tissue; however, there did not appear to be evidence that testing for (b)(4) had been performed prior to the release of these products, as required by (b)(4).\nBello determines donor eligibility upon review of relevant medical records per your contract agreement with (b)(4). The “Donor Eligibility Criteria” documents (effective date 08\u002F15\u002F2023) submitted with your January 8, 2026, response and also collected during the inspection do not include “qualifiers\u002Fcomments” for Transmissible Spongiform Encephalopathy (TSE). In accordance with 21 CFR 1271.75(a)(1)(iv), all donors of cells or tissues, except as provided under 1271.90, must be screened by reviewing the donor’s relevant medical records for risk factors for, and clinical evidence of, relevant communicable disease agents and diseases, including human transmissible spongiform encephalopathy, including Creutzfeldt-Jakob disease. Additionally, FDA Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (August 2007)9 recommends screening donors for TSE, including Creutzfeldt-Jakob disease (CJD) and variant CJD (vCJD), by asking if donors have been diagnosed with dementia or any degenerative or demyelinating diseases of the central nervous system or other neurological disease of unknown etiology. For additional information and recommendations intended to assist establishments with complying with all requirements in 21 CFR part 1271, subpart C, please refer to the guidance.\nConclusion\nNeither this letter nor the observations noted on the Form FDA-483s for both Bello and Regen, which were discussed with you at the conclusion of the inspections, are intended to be all-inclusive lists of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with the FD&C Act, PHS Act, and all applicable regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\nPlease submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\nSend your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nVincent Amatrudo\nActing Director\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\nCc: (b)(4)\n________________________\n1 During the inspections, you informed FDA that R3 Medical Companies is the parent company of these companies co-located at the same business address: Bello, Regen, R3 Stem Cell, LLC and R3 Anti-Aging Scottsdale LLC. You bear primary responsibility for the business operations at each of the aforementioned entities.\n2 Greene Technologies, LLC, for which you are the co-owner and majority holder, along with Ms. Deborah Greene, invests in the referenced entities and other R3 Anti-Aging LLC clinics located at 5020 Thoroughbred Lane, Brentwood, TN 37027 and 9301 Wilshire Boulevard Penthouse, Beverly Hills, CA 90210. The referenced entities function together with Bello as the manufacturer and Regen as the private label distributor to the three R3 Anti-Aging clinics, healthcare professionals, and other clinics as direct-to-customers and through R3 Stem Cell’s partnership program, R3 Alliance Partner. We note you are also the current Chief Executive Officer (CEO) of R3 Anti-Aging & MedSpa Nashville, LLC (located at 5020 Thoroughbred Lane, Brentwood, TN 37027) and R3 Anti-Aging Beverly Hills, LLC (located at 9301 Wilshire Boulevard Penthouse, Beverly Hills, CA 90210).\n3 Regen markets ReBellaXO and ReBellaXOL as exosome products; however, products manufactured by Bello use the same starting material and manufacturing process (with the exception of an added lyophilization step for ReBellaXOL), which does not appear would isolate exosomes.\n4 ReBellaXOL was also labeled as ReBellaGF by Bello at the time of the inspections.\n5 As of August 14, 2026, it appears that the Regen Suppliers website www.regensuppliers.com is no longer accessible with a “404, Not Found.” message displayed.\n6 Because your products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a) for each product.\n7 Although products are contract manufactured for Regen, Regen’s activities, as described above, constitute manufacturing under 21 CFR 210.3(b)(12). Regen is therefore subject to CGMP requirements.\n8 Bello markets BelloXO and BelloXOL as exosome products; however, it does not appear that the manufacturing process would isolate exosomes.\n9 See https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Feligibility-determination-donors-human-cells-tissues-and-cellular-and-tissue-based-products.","R3 Medical Companies","r3-medical-companies-726330-08142026","2026-09-07T05:14:13.57002+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fr3-medical-companies-726330-08142026","2026-10-26T08:09:46.375146+00:00","2026-08-25","726330","Biologics","David L. Greene, M.D.","2026-09-07T05:15:14.733+00:00","Via UPS and EMAIL","CBER 26-726330","2026-08-14",{"id":77,"raw":78,"subject":83,"body_html":84,"body_text":85,"firm_name":86,"letter_id":87,"created_at":88,"fei_number":19,"letter_url":89,"updated_at":90,"action_type":22,"case_status":23,"posted_date":91,"marcs_cms_no":92,"product_type":93,"closeout_date":19,"issuing_office":82,"recipient_name":94,"body_fetched_at":95,"delivery_method":96,"recipient_title":19,"reference_number":19,"action_taken_date":97,"medical_device_id":19,"response_letter_date":19},1938,[79,80,81,82,83,13,13,13],"\u003Ctime datetime=\"2023-08-15T13:20:00Z\">08\u002F15\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-08-09T04:00:00Z\">08\u002F09\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Falva-amco-pharmacal-companies-llc-663727-08092023\">ALVA-AMCO Pharmacal Companies, LLC\u003C\u002Fa>","Office of Unapproved Drugs and Labeling Compliance","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Micah S. Gerchenson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>ALVA-AMCO Pharmacal Companies, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>7711 Merrimac Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Niles\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60714-3423\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:mgerchenson@kobayashi.com\"> mgerchenson@kobayashi.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:customer_service@alva-amco.com\"> customer_service@alva-amco.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Unapproved Drugs and Labeling Compliance\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 9, 2023\u003C\u002Fp>\n\n\u003Cp>RE: 663727\u003C\u002Fp>\n\n\u003Cp>Dear Micah S. Gerchenson:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address www.nauzenekids.com in May 2023. The FDA has observed that your firm offers “Nauzene Kids” for sale in the United States. Based on our review of your website and product label, this product is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>Please also reference warning letter 654226, issued on July 26, 2023, to Denison Pharmaceuticals, LLC, that summarized significant violations of current good manufacturing practice (CGMP) regulations for its finished pharmaceuticals.\u003C\u002Fp>\n\n\u003Cp>Your “Nauzene Kids” product is particularly concerning from a public health perspective because of these CGMP violations and because it is directed for use in young children.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on a review of the product label and your website www.nauzenekids.com, your “Nauzene Kids” product is a drug under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>Examples of claims that provide evidence of the intended use of this product as a drug include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>From the product label:\u003Cbr>\n• “For Nausea &amp; Upset Tummies”\u003Cbr>\n• “Relief of Nauseas From:\u003Cbr>\n&nbsp; &nbsp; o ‘Car Sickness’\u003Cbr>\n&nbsp; &nbsp; o ‘Stomach Flu’\u003Cbr>\n&nbsp; &nbsp; o ‘Upset Tummies’”\u003Cbr>\n• “Promptly relieves nausea and upset tummies – even from the ‘stomach flu’ and ‘car sickness’”\u003Cbr>\n• “For the relief of upset stomach and nausea, including that due to ‘stomach flu,’ ‘car sickness’ or overindulgences in food or drink.”\u003Cbr>\n\u003Cbr>\nFrom the website www.nauzenekids.com:\u003Cbr>\n• “The Easy Fix for Upset Stomachs &amp; Nausea”\u003Cbr>\n&nbsp; &nbsp; o “Trusted Relief for Upset Stomachs Caused by . . . Diet . . . Stomach Bug . . . Motion Sickness . . . Nervous Stomach”\u003C\u002Fp>\n\n\u003Cp>“Your “Nauzene Kids” product is not generally recognized as safe and effective (GRASE) for its above referenced uses and, therefore, the product is a “new drug” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d). No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for this product. Accordingly, the introduction or delivery for introduction into interstate commerce of this product violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>We recognize that “Nauzene Kids” is labeled as a homeopathic drug with active ingredients measured in homeopathic strengths. Under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&amp;C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by e-mail to FDAADVISORY@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CAPT Tina Smith\u003Cbr>\nActing Director\u003Cbr>\nOffice of Unapproved and Labeling Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMicah S. Gerchenson\n\nALVA-AMCO Pharmacal Companies, LLC\n\n7711 Merrimac Avenue\n\nNiles, IL 60714-3423\n\nUnited States\n\nmgerchenson@kobayashi.com\n\ncustomer_service@alva-amco.com\n\nIssuing Office:\n\nOffice of Unapproved Drugs and Labeling Compliance\n\nUnited States\n\nWARNING LETTER\n\nAugust 9, 2023\n\nRE: 663727\n\nDear Micah S. Gerchenson:\n\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address www.nauzenekids.com in May 2023. The FDA has observed that your firm offers “Nauzene Kids” for sale in the United States. Based on our review of your website and product label, this product is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nPlease also reference warning letter 654226, issued on July 26, 2023, to Denison Pharmaceuticals, LLC, that summarized significant violations of current good manufacturing practice (CGMP) regulations for its finished pharmaceuticals.\n\nYour “Nauzene Kids” product is particularly concerning from a public health perspective because of these CGMP violations and because it is directed for use in young children.\n\nUnapproved New Drugs\n\nBased on a review of the product label and your website www.nauzenekids.com, your “Nauzene Kids” product is a drug under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body.\n\nExamples of claims that provide evidence of the intended use of this product as a drug include, but may not be limited to, the following:\n\nFrom the product label:\n\n• “For Nausea & Upset Tummies”\n\n• “Relief of Nauseas From:\n\no ‘Car Sickness’\n\no ‘Stomach Flu’\n\no ‘Upset Tummies’”\n\n• “Promptly relieves nausea and upset tummies – even from the ‘stomach flu’ and ‘car sickness’”\n\n• “For the relief of upset stomach and nausea, including that due to ‘stomach flu,’ ‘car sickness’ or overindulgences in food or drink.”\n\nFrom the website www.nauzenekids.com:\n\n• “The Easy Fix for Upset Stomachs & Nausea”\n\no “Trusted Relief for Upset Stomachs Caused by . . . Diet . . . Stomach Bug . . . Motion Sickness . . . Nervous Stomach”\n\n“Your “Nauzene Kids” product is not generally recognized as safe and effective (GRASE) for its above referenced uses and, therefore, the product is a “new drug” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d). No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for this product. Accordingly, the introduction or delivery for introduction into interstate commerce of this product violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nWe recognize that “Nauzene Kids” is labeled as a homeopathic drug with active ingredients measured in homeopathic strengths. Under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by e-mail to FDAADVISORY@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nCAPT Tina Smith\n\nActing Director\n\nOffice of Unapproved and Labeling Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration","ALVA-AMCO Pharmacal Companies, LLC","alva-amco-pharmacal-companies-llc-663727-08092023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Falva-amco-pharmacal-companies-llc-663727-08092023","2026-10-26T08:07:53.398583+00:00","2023-08-15","663727","Drugs","Micah S. Gerchenson","2026-08-20T00:47:19.358+00:00","Via Email","2023-08-09",{"id":99,"raw":100,"subject":105,"body_html":106,"body_text":107,"firm_name":108,"letter_id":109,"created_at":43,"fei_number":19,"letter_url":110,"updated_at":111,"action_type":22,"case_status":23,"posted_date":112,"marcs_cms_no":113,"product_type":93,"closeout_date":19,"issuing_office":104,"recipient_name":114,"body_fetched_at":115,"delivery_method":116,"recipient_title":19,"reference_number":117,"action_taken_date":118,"medical_device_id":19,"response_letter_date":19},516,[101,102,103,104,105,13,13,13],"\u003Ctime datetime=\"2025-10-28T04:00:00Z\">10\u002F28\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-10-16T04:00:00Z\">10\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftranzonic-companiesinnocore-sales-marketing-inc-712258-10162025\">The Tranzonic Companies\u002FInnocore Sales &amp; Marketing Inc.\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail - Delivery and Read Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-07\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Robert Kibbe\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>The Tranzonic Companies\u002FInnocore Sales &amp; Marketing Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>26301 Curtiss Wright Parkway\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Cleveland\u003C\u002Fspan>, \u003Cspan>OH\u003C\u002Fspan> \u003Cspan>44143\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-07\u003C\u002Fp>\u003Cp>October 16, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Kibbe:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Innocore Sales &amp; Marketing, Inc., FEI 3010034070, located at 399 Woodall Way, Woodstock, N4T 0K9, Ontario, Canada, from April 22 to 25, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your May 16, 2025, response to our Form FDA 483 in detail.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release. Your firm also failed to conduct, for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures over-the-counter drug products such as \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You failed to conduct adequate finished product release testing for each batch of your drug product including, but not limited to, testing the identity and strength of the active ingredient, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and testing for objectionable microorganisms.\u003C\u002Fp>\u003Cp>In your response, you state that you developed and will validate the titration and Fourier- transform infrared spectroscopy test methods, used for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> assay and identification. You also state that you will investigate microbiological testing options for your finished drug products prior to release.\u003C\u002Fp>\u003Cp>Your response is inadequate because it lacks sufficient details regarding specific tests for each finished drug batch and fails to include a risk assessment or retrospective review of products released without appropriate testing.\u003C\u002Fp>\u003Cp>Without adequate finished product release testing, you do not have scientific evidence that each batch of drug product conforms to appropriate specifications before release.\u003C\u002Fp>\u003Cp>In your response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>A list of chemical and microbiological specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\u003Cbr>o An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to conduct adequate testing on incoming components, including an appropriate identity test of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, a component at higher risk for diethylene glycol (DEG) and ethylene glycol (EG) contamination. Identity testing for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and certain other high-risk drug components includes a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform adequate identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in manufacture of your drug product.\u003C\u002Fp>\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Ftesting-glycerin-propylene-glycol-maltitol-solution-hydrogenated-starch-hydrolysate-sorbitol.\u003C\u002Fp>\u003Cp>In your response, you state you have revised your raw material procedures regarding the component, \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Your response is inadequate because you failed to include a comprehensive review of your entire materials system, including test methods and compendial requirements. Furthermore, you did not consider testing retains of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and lacked a risk assessment of using inadequately tested \u003Cstrong>(b)(4)\u003C\u002Fstrong> in the manufacture of your distributed drug products.\u003C\u002Fp>\u003Cp>Without adequate testing, you lack scientific evidence that the components or drug products conform to appropriate specifications prior to use in the drug products you manufacture.\u003C\u002Fp>\u003Cp>In your response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\u003C\u002Fli>\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective actions and preventive actions that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificate of analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\u003C\u002Fli>\u003Cli>The chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\u003C\u002Fli>\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products (21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You lacked an adequate stability testing program for your drug products. For example, you lacked sufficient data to support the labeled expiry. You also lacked stability chambers to adequately store your stability samples. Further, the stability samples are not stored in the same container closure system in which your drug product is marketed.\u003C\u002Fp>\u003Cp>In your response, you state that you updated your stability program SOP to include requirements for finished packaged drug product stability data and that you anticipate commencing your stability program by \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Your response is inadequate because it lacks sufficient detail and does not provide a retrospective risk assessment for your drug products released without adequate stability testing.\u003C\u002Fp>\u003Cp>Without appropriate stability studies, you do not have scientific evidence to support whether your drug products meet established specifications and retain their quality attributes throughout their assigned shelf life.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment and corrective action and preventive action plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>o Stability-indicating methods\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003Cbr>o An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\u003Cbr>o Detailed definition of the specific attributes to be tested at each station (timepoint).\u003C\u002Fli>\u003Cli>All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to establish an adequate quality unit (QU) with the responsibilities and authority to oversee the manufacturing of drug products. For example, the QU failed to ensure:\u003C\u002Fp>\u003Cul>\u003Cli>Establishment of an adequate cleaning and maintenance program for your manufacturing equipment and instruments. (21 CFR 211.67(a))\u003C\u002Fli>\u003Cli>Establishment of adequate batch records to include verification checks, appropriately detailed instructions, and labeling. (21 CFR 211.188)\u003C\u002Fli>\u003Cli>Adequate investigations with sustainable corrective actions including, but not limited to, unknown residues on equipment and out of specification cleaning rinse samples. (21 CFR 211.192)\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations.\u003C\u002Fp>\u003Cp>In response to this letter, provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fp>\u003Cul>\u003Cli>A determination of whether procedures used by your firm are robust and appropriate\u003C\u002Fli>\u003Cli>Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003C\u002Fli>\u003Cli>A complete and final review of each batch and its related information before the QU disposition decision\u003C\u002Fli>\u003Cli>Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Also, describe how top management supports quality assurance and reliable operations including, but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fp>\u003Cp>\u003Cstrong>Repeat Observations at Facility\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In a June 2019 inspection, FDA cited similar CGMP observations. You proposed specific remediation for these observations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Innocore Sales &amp; Marketing, Inc., 399 Woodall Way, Woodstock, N4T 0K9, Ontario, Canada, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3010034070 and ATTN: Christopher M. Jenner.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail - Delivery and Read Receipt Requested\n\nReference #:\n\n320-26-07\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Robert Kibbe\n\nRecipient Title\n\nPresident and CEO\n\nThe Tranzonic Companies\u002FInnocore Sales & Marketing Inc.\n\n26301 Curtiss Wright Parkway\n\nCleveland, OH 44143\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-07\nOctober 16, 2025\nDear Mr. Kibbe:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Innocore Sales & Marketing, Inc., FEI 3010034070, located at 399 Woodall Way, Woodstock, N4T 0K9, Ontario, Canada, from April 22 to 25, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your May 16, 2025, response to our Form FDA 483 in detail.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release. Your firm also failed to conduct, for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).\nYour firm manufactures over-the-counter drug products such as (b)(4). You failed to conduct adequate finished product release testing for each batch of your drug product including, but not limited to, testing the identity and strength of the active ingredient, (b)(4), and testing for objectionable microorganisms.\nIn your response, you state that you developed and will validate the titration and Fourier- transform infrared spectroscopy test methods, used for the (b)(4) assay and identification. You also state that you will investigate microbiological testing options for your finished drug products prior to release.\nYour response is inadequate because it lacks sufficient details regarding specific tests for each finished drug batch and fails to include a risk assessment or retrospective review of products released without appropriate testing.\nWithout adequate finished product release testing, you do not have scientific evidence that each batch of drug product conforms to appropriate specifications before release.\nIn your response to this letter, provide:\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nA list of chemical and microbiological specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\no An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n2. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\nYou failed to conduct adequate testing on incoming components, including an appropriate identity test of (b)(4), a component at higher risk for diethylene glycol (DEG) and ethylene glycol (EG) contamination. Identity testing for (b)(4), and certain other high-risk drug components includes a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform adequate identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in manufacture of your drug product.\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Ftesting-glycerin-propylene-glycol-maltitol-solution-hydrogenated-starch-hydrolysate-sorbitol.\nIn your response, you state you have revised your raw material procedures regarding the component, (b)(4).\nYour response is inadequate because you failed to include a comprehensive review of your entire materials system, including test methods and compendial requirements. Furthermore, you did not consider testing retains of your (b)(4) and lacked a risk assessment of using inadequately tested (b)(4) in the manufacture of your distributed drug products.\nWithout adequate testing, you lack scientific evidence that the components or drug products conform to appropriate specifications prior to use in the drug products you manufacture.\nIn your response to this letter, provide:\nA commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective actions and preventive actions that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificate of analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of (b)(4), and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\nThe chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\n3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products (21 CFR 211.166(a)).\nYou lacked an adequate stability testing program for your drug products. For example, you lacked sufficient data to support the labeled expiry. You also lacked stability chambers to adequately store your stability samples. Further, the stability samples are not stored in the same container closure system in which your drug product is marketed.\nIn your response, you state that you updated your stability program SOP to include requirements for finished packaged drug product stability data and that you anticipate commencing your stability program by (b)(4).\nYour response is inadequate because it lacks sufficient detail and does not provide a retrospective risk assessment for your drug products released without adequate stability testing.\nWithout appropriate stability studies, you do not have scientific evidence to support whether your drug products meet established specifications and retain their quality attributes throughout their assigned shelf life.\nIn response to this letter, provide:\nA comprehensive, independent assessment and corrective action and preventive action plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\no Stability-indicating methods\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\no Detailed definition of the specific attributes to be tested at each station (timepoint).\nAll procedures that describe these and other elements of your remediated stability program.\n4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour firm failed to establish an adequate quality unit (QU) with the responsibilities and authority to oversee the manufacturing of drug products. For example, the QU failed to ensure:\nEstablishment of an adequate cleaning and maintenance program for your manufacturing equipment and instruments. (21 CFR 211.67(a))\nEstablishment of adequate batch records to include verification checks, appropriately detailed instructions, and labeling. (21 CFR 211.188)\nAdequate investigations with sustainable corrective actions including, but not limited to, unknown residues on equipment and out of specification cleaning rinse samples. (21 CFR 211.192)\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations.\nIn response to this letter, provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\nA determination of whether procedures used by your firm are robust and appropriate\nProvisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\nA complete and final review of each batch and its related information before the QU disposition decision\nOversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\nAlso, describe how top management supports quality assurance and reliable operations including, but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\nRepeat Observations at Facility\nIn a June 2019 inspection, FDA cited similar CGMP observations. You proposed specific remediation for these observations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Innocore Sales & Marketing, Inc., 399 Woodall Way, Woodstock, N4T 0K9, Ontario, Canada, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3010034070 and ATTN: Christopher M. Jenner.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","The Tranzonic Companies\u002FInnocore Sales & Marketing Inc.","tranzonic-companiesinnocore-sales-marketing-inc-712258-10162025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftranzonic-companiesinnocore-sales-marketing-inc-712258-10162025","2026-10-26T08:10:14.522384+00:00","2025-10-28","712258","Mr. Robert Kibbe","2026-08-19T16:12:48.946+00:00","Via Electronic Mail - Delivery and Read Receipt Requested","320-26-07","2025-10-16",5,{"510k":121,"classification":122,"enforcement":123,"event":124,"event_backfill":125,"pma":126,"warning_letter":127},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]